BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
07 août 2019 10h00 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...
DNV GL Healthcare Focuses on Overcoming Antimicrobial Resistance in Nation's Hospitals
29 mai 2019 16h27 HE
|
DNV GL Business Assurance USA, Inc.
MILFORD, OHIO, May 29, 2019 (GLOBE NEWSWIRE) -- As the Centers for Disease Control and Prevention (CDC) ramps up the nation’s attempts to neutralize antibiotic/anti-microbial resistance (AMR) in...
Louisiana Restaurants to Disclose Use of Foreign Shrimp and Crawfish
29 mai 2019 13h28 HE
|
American Shrimp Processors Association
BILOXI, Miss., May 29, 2019 (GLOBE NEWSWIRE) -- In a move to protect Louisiana consumers from “the health risks associated chemicals and residues in imported seafood,” the Louisiana Senate...
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
18 mars 2019 11h00 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN)...
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
14 mars 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...
BioAegis Therapeutics Expands Phase 1b/2a Community-Acquired Pneumonia Study to the Republic of Georgia —Successfully Completes Second of Four Dosing Cohorts
07 févr. 2019 09h17 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study
01 févr. 2019 10h53 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of...
Fedora Pharmaceuticals and Meiji Seika Pharma Sign Basic Agreement to Establish NacuGen Therapeutics Inc., a Joint Venture to Develop and Commercialize Nacubactam for Bacterial Infections
07 janv. 2019 09h00 HE
|
Nacugen Therapeutics, Inc.
EDMONTON, Alberta and Tokyo , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. (headquarters: Edmonton, Alberta, Canada; Chief Executive Officer: Christopher G. Micetich, hereinafter...
New Genomic Technology Advances Fight Against Global Health Threat of Antibiotic Resistance
06 déc. 2018 09h14 HE
|
Phase Genomics
SEATTLE, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Phase Genomics, the leader in proximity-ligation genome assembly technology released an antimicrobial resistance (AMR) study led by researchers from the...
BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round
18 sept. 2018 08h52 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...